Changes of PI3K/AKT/BCL2 signaling proteins in congenital Giant Nevi: Melanocytes contribute to their increased survival and integrity

Journal of Receptors and Signal Transduction

Volumn 33, Issue 6, 2013, Pages 359-366

  Drukker, Lior ^a   Margulis, Alexander ^a   Chaouat, Malka ^a   Levitzki, Rubina ^a   Maiorenko, Elena ^a   Ben Bassat, Hannah ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Cell growth; CGN; Melanocytes; PI3K AKT BCL2; Signaling pathways

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; WNT PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL POPULATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONGENITAL GIANT NEVUS; CONGENITAL NEVUS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MELANOCYTE; PLASTIC SURGERY; PRESCHOOL CHILD; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN; STARVATION; TISSUE EXPANSION; WESTERN BLOTTING;

APOPTOSIS; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOCYTES; MELANOMA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84890210617     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.838785     Document Type: Article

References (43)

1. Zaal LH, Mooi WJ, Sillevis Smitt JH, van der Horst CM. Classification of congenital melanocytic naevi and malignant transformation: a review of the literature. Br J Plast Surg 2004; 57:707-19.
2. Tannous ZS, Mihm Jr MC, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005; 52:197-203.
3. Marghoob AA, Borrego JP, Halpern AC. Congenital melanocytic nevi: treatment modalities and management options. Semin Cutan Med Surg 2007;26:231-40.
4. Arneja JS, Gosain AK. Giant congenital melanocytic nevi. Plast Reconstr Surg 2009;124:1e-13e.
5. Chung C, Forte AJ, Narayan D, Persing J. Giant nevi: a review. J Craniofac Surg 2006;17:1210-15.
6. Danarti R, König A, Happle R. Large congenital melanocytic nevi may reflect paradominant inheritance implying allelic loss. Eur J Dermatol 2003;13:430-2.
7. Takata M, Saida T. Genetic alterations in melanocytic tumors. J Dermatol Sci 2006;43:1-10.
8. Kim HK, Kim YK, Song IS, et al. Human giant congenital melanocytic nevus exhibits potential proteomic alterations leading to melanotumorigenesis. Proteome Sci 2012;10:50.
9. Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 2010;23: 64-71.
10. Shada AL, Molhoek KR, Slingluff Jr CL. Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J 2010;16:360-6.
11. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010;10:458-77.
12. Larribere L, Khaled M, Tartare-Deckert S, et al. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 2004;11:1084-91.
13. Oka M, Kageyama A, Fukunaga M, et al. Phosphatidylinositol 3-kinase/Akt-dependent and -independent protection against apoptosis in normal human melanocytes. J Invest Dermatol 2004;123: 930-6.
14. Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007;282:11221-9.
15. Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117:719-29.
16. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008;55:165-76.
17. Lucero OM, Dawson DW, Moon RT, Chien AJ. A re-evaluation of the ''oncogenic'' nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 2010;12: 314-18.
18. Shushan A, Rojansky N, Laufer N, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 2004;19:1957-67.
19. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, et al. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res 1997;57:3741-50.
20. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies. Int J Oncol 2009;34: 1481-9.
21. Schiaffino MV. Signaling pathways in melanosome biogenesis and pathology. Int J Biochem Cell Biol 2010;42:1094-104.
22. Lin SJ, Jee SH, Hsiao WC, et al. Enhanced cell survival of melanocyte spheroids in serum starvation condition. Biomaterials 2006;27:1462-69.
23. Eberle J, Kurbanov BM, Hossini AM, et al. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Update 2007;10:218-34.
24. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009;22:400-19.
25. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007;64:1930-44.
26. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006;79:173-89.
27. Satyamoorthy K, Li G, Vaidya B, et al. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001;61:7318-24.
28. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003;73:689-701.
29. Zanella F, Renner O, García B, et al. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 2010;29:2973-82.
30. Delmas V, Beermann F, Martinozzi S, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007;21:2923-35.
31. Stefanaki C, Antoniou C, Stefanaki K, et al. Bcl-2 and Bax in congenital naevi. Br J Dermatol 2006;154:1175-9.
32. Leverkus M, Gollnick H. ''Bak (and Bax) to the future'' - of primary melanoma prognosis? J Invest Dermatol 2006;126: 1212-24.
33. Leiter U, Schmid RM, Kaskel P, et al. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000; 292:225-32.
34. Zhuang L, Lee CS, Scolyer RA, et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007;20:416-26.
35. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003;20:531-9.
36. Buchakjian MR, Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 2010;11:715-27.
37. Huang W, Chang HY, Fei T, et al. GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 2007;26:2471-82.
38. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001;54: 229-35.
39. Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. Curr Top Dev Biol 2010;92:1-29 [review].
40. Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009;69:5312-20.
41. Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005;115:3166-76.
42. Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 2006;66:4182-90.
43. Bedogni B, Warneke JA, Nickoloff BJ, et al. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008; 118:3660-70.